A recent study conducted by researchers from Charite – Universitätsmedizin Berlin has shed light on the impact of low-dose glucocorticoids, a type of steroid hormone, on individuals with rheumatoid arthritis (RA).
With around 18 million people worldwide affected by this autoimmune disease, finding effective and safe treatments is crucial. Glucocorticoids are commonly used to manage RA symptoms due to their anti-inflammatory properties, but concerns about potential side effects such as weight gain and high blood pressure have made some patients hesitant.
The study, published in the Annals of Internal Medicine, analyzed data from five randomized controlled trials involving over 1,112 participants across 12 European countries.
The research focused on evaluating the effects of low-dose glucocorticoid treatment on body weight and blood pressure over a two-year period. The findings revealed that participants on low-dose glucocorticoids experienced a modest weight gain of only about 2 pounds compared to those on placebo, with no significant difference in blood pressure between the two groups.
This research provides reassuring evidence that low-dose glucocorticoids do not lead to substantial weight gain or elevated blood pressure, addressing a common concern among RA patients and healthcare providers.
However, experts like Dr. David R. Karp and Dr. Medhat Mikhael suggest that further studies are needed to explore the long-term effects of such treatments and their impact on diverse populations, as well as comparisons with other RA therapies.
The goal is to ensure that patients with RA have access to safe and effective treatment options that minimize the risk of adverse side effects.
Source: Medical News Today
Image by Darko Stojanovic from Pixabay
